LGALS9 and neoplasm: As a downstream effector of peroxisome proliferator-activated receptor γ (PPARγ), Gal-9 inhibits key steps in tumor progression, including ECM invasion, cellular detachment from the primary tumor, and adherence to the vascular endothelium.